 "Bharat Biotech, Covaxin")
The Coalition for Epidemic Preparedness Innovations (CEPI), a partnership between public, private, philanthropic organisations to develop vaccines against future epidemics, has partnered with Hyderabad based Bharat Biotech, the University of Sydney and ExcellGene of Switzerland to develop a ‘variant-proof’ Covid-19 vaccine.
Bharat Biotech, University of Sydney and ExcellGene consortium is the latest award that CEPI made under its $200 mn programme to advance the development of vaccines that would provide broad protection against the Sars-CoV-2 variants and also other betacoronaviruses.
CEPI has till date announced funding for nine such projects including the Bharat Biotech one.
Under this initiative, CEPI will
